Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain-Barré syndrome patients.
Guillain-Barré syndrome (GBS) is an acute, autoimmune inflammatory disorder of peripheral nervous system characterized by a severe functional motor weakness. Treatment with intravenous immunoglobulin (IVIg) is one of the approved and preferred therapeutic strategies for GBS. However, the mechanisms underlying the therapeutic benefit with IVIg in GBS are not completely understood. In the present study, we observed that GBS patients have increased frequencies of Th1 and Th17 cells, but reduced number of Foxp3(+) regulatory T cells (Treg cells) with defective functions. We show that IVIg treatment in GBS patients results in a marked reduction in the frequency of Th1 and Th17 cells with a concomitant expansion of Treg cells. Importantly, IVIg-expanded Treg cells exhibited an increased T cell suppressive function. Together our results demonstrate that therapeutic benefit of IVIg in GBS patients implicates the reciprocal regulation of Th1/Th17 and Treg cells.
Institut National de la Santé et de la Recherche Médicale Unité 1138, 75006, Paris, France.
Mohan S
MS
Maddur
Magalie
M
Rabin
Pushpa
P
Hegde
Francis
F
Bolgert
Moneger
M
Guy
Jean-Michel
JM
Vallat
Laurent
L
Magy
Jagadeesh
J
Bayry
Srini V
SV
Kaveri
D000368:Aged; D016022:Case-Control Studies; D020275:Guillain-Barre Syndrome / Q000188:drug therapy* / Q000276:immunology* / Q000503:physiopathology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000494:pharmacology* / Q000627:therapeutic use*; D056747:Immunomodulation / Q000187:drug effects*; D016130:Immunophenotyping; D018655:Lymphocyte Count; D008875:Middle Aged; D009043:Motor Activity / Q000187:drug effects; D016176:T-Lymphocyte Subsets / Q000187:drug effects* / Q000276:immunology* / Q000378:metabolism; D050378:T-Lymphocytes, Regulatory; D018417:Th1 Cells; D058504:Th17 Cells
D016756:Immunoglobulins, Intravenous